Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 5Triple Negative Breast Neoplasms 2Pathologic Complete Response 1Neoplasms 1Hemangiosarcoma 1HER2-positive Breast Cancer 1Brain Neoplasms 1

Interventions

Trastuzumab 19pyrotinib 14pertuzumab 8Docetaxel 7Paclitaxel 6Capecitabine 4Carboplatin 3neratinib 2Protons 2Neoadjuvant Therapy 2Fulvestrant 2Ado-Trastuzumab Emtansine 2tucatinib 1trastuzumab deruxtecan 1pegfilgrastim 1palbociclib 1inavolisib 1exemestane 1envafolimab 1dalpiciclib 1atezolizumab 1Taxoids 1Metformin 1Leuprolide 1Letrozole 1Isovaleryl-CoA Dehydrogenase 1Goserelin 1Genetic Testing 1Fluorodeoxyglucose F18 1Enfuvirtide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × HER2-positive Breast Cancer × ARX788 × Clear all
NCT05426486 2024-10-30

A Study of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients

Shengjing Hospital

Phase 2/3 Active not recruiting
136 enrolled
Breast

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡